Why Screening Colonoscopies Are the Most Common Billing Mistake in Gastroenterology
Roughly a quarter of screening colonoscopies end with a polyp coming out — one peer-reviewed analysis of screening colonoscopies in patients aged 50–75 found adjusted polypectomy rates between 22.6% and 26.2% depending on how "screening" was defined (National Institutes of Health / PMC). Which means "screening colonoscopy" and "the claim we actually need to bill" are frequently two different things by the time the patient is in recovery. Getting the conversion right isn't a documentation nicety. It's the difference between a patient who was promised a no-cost preventive screening and a patient who gets a bill they weren't expecting, and between a practice that gets paid correctly and one that's writing off revenue or fielding a complaint.
Medicare and commercial plans use different modifiers for the same event
When a screening colonoscopy converts to diagnostic or therapeutic — most often because a polyp was found and removed — the modifier that has to go on the therapeutic code depends on who's paying. For Medicare, that's modifier PT. For commercial insurance, it's modifier 33 (American Gastroenterological Association). The two aren't interchangeable, and a claim scrubber or biller working from a single mental model of "how we code a converted colonoscopy" will get roughly half of these wrong by definition — right for one payer type, automatically incorrect for the other.
Medicare's cost-sharing exception is still being phased out, not gone
Even coded correctly, a converted screening colonoscopy under Medicare isn't fully cost-share-free yet. Medicare beneficiaries are responsible for a declining share of the cost when a polyp is removed during a screening colonoscopy — 15% from 2023 through 2026, dropping to 10% from 2027 through 2029, and reaching full coverage only in 2030 (American Gastroenterological Association). That's a detail that's easy to miss if a practice assumes the ACA's zero-cost-sharing preventive rule applies identically across Medicare and commercial plans — it doesn't, and a patient billed as though it does is a patient who will call to dispute it.
Commercial plans don't get the same multi-year phase-in
On the commercial side, modifier 33 is what triggers the ACA's zero-cost-sharing treatment for a service that started as preventive — there's no equivalent phase-down schedule to track, but there is a hard dependency on the modifier being applied correctly in the first place. Miss it, and a claim that should have processed as fully covered preventive care processes as a standard diagnostic procedure with normal patient cost-sharing attached instead.
The fix has to happen at coding, not after the denial or the complaint
Reconstructing screening-versus-diagnostic intent from an operative note weeks after the claim was submitted is a losing pattern — it produces both revenue leakage and the kind of patient billing surprise that generates complaints and, increasingly, scrutiny under No Surprises Act-adjacent expectations around preventive care billing. The distinction has to be captured and coded correctly the first time, payer type by payer type, at the moment the claim is built — not identified during an appeal.
See how we approach gastroenterology billing and revenue cycle management for practices and endoscopy centers of any size.
Industry statistics cited above are drawn from PMC/National Institutes of Health research and American Gastroenterological Association coding guidance as noted and are not medbpo360's own client data.